ABRT Stock Overview
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Albert Labs International Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.015 |
52 Week High | CA$0.05 |
52 Week Low | CA$0.005 |
Beta | 4.31 |
1 Month Change | 0% |
3 Month Change | 50.00% |
1 Year Change | -72.73% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -94.00% |
Recent News & Updates
Recent updates
Shareholder Returns
ABRT | CA Biotechs | CA Market | |
---|---|---|---|
7D | 0% | 1.1% | 1.3% |
1Y | -72.7% | -36.3% | 9.1% |
Return vs Industry: ABRT underperformed the Canadian Biotechs industry which returned -35.8% over the past year.
Return vs Market: ABRT underperformed the Canadian Market which returned 9.6% over the past year.
Price Volatility
ABRT volatility | |
---|---|
ABRT Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 8.8% |
10% most volatile stocks in CA Market | 17.7% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: ABRT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ABRT's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 3 | Chand Jagpal | albertlabs.com |
Albert Labs International Corp., a biopharmaceutical drug discovery company, researches and develops drugs for psychedelic-assisted therapy for patients with urgent and unmet needs in Canada and the United Kingdom. It develops KRN-101, is a solution for cancer-related anxiety. The company is based in Burnaby, Canada.
Albert Labs International Corp. Fundamentals Summary
ABRT fundamental statistics | |
---|---|
Market cap | CA$1.12m |
Earnings (TTM) | -CA$2.31m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs ABRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABRT income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$2.31m |
Earnings | -CA$2.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.031 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -2.3% |
How did ABRT perform over the long term?
See historical performance and comparison